How many drugs are losing patent protection in 2026?

Drug Landscape tracks 58 marketed drugs with at least one patent expiring in 2026, sourced from FDA Orange Book + USPTO Patent Public Search.

What is a patent cliff?

A patent cliff is the year a major branded drug loses primary patent protection, opening the market to generic or biosimilar entry. Originator revenue typically drops 30–80% within 24 months, depending on the drug class and the strength of secondary patents.

Are these forecasts accurate?

Patent expiry dates are deterministic — they're the listed expiry from the Orange Book or USPTO record. Generic / biosimilar entry timing depends on litigation outcomes, paragraph IV challenges, settlements, and exclusivity periods which can shift the practical "cliff" by months to years.

Last reviewed 2026-05-14 · How we verify

2026 Pharmaceutical Patent Cliff

58 marketed drugs with patents expiring in 2026, joined to sponsor + therapeutic area + drug class. Live tracking. Sourced from FDA Orange Book + USPTO Patent Public Search.

58 drugs 156 patents 11 therapeutic areas Live · current year

By therapeutic area

Oncology (17)

2026-01-20 — Torisel · Pfizer · temsirolimus
2026-01-24 — Xyosted (Autoinjector) · Endo · Androgen
2026-01-24 — Trexall · Generic (originally Lederle Laboratories) · Antifolate, DMARD · Formulation
2026-01-27 — Sandimmune · Novartis · Calcineurin Inhibitor Immunosuppressant [EPC]
2026-02-21 — Taxol · Pfizer · Microtubule Inhibitor [EPC] · Method of Use
2026-02-21 — Taxol · Pfizer · Microtubule Inhibitor
2026-02-26 — Flonase · GSK (GlaxoSmithKline) · Inhaled/intranasal corticosteroid · Formulation
2026-04-04 — Elocon · Merck & Co. · Corticosteroid · Method of Use
2026-05-01 — Afinitor · Novartis · Kinase Inhibitor [EPC] · Compound
2026-05-15 — Xtandi · Astellas Pharma · Androgen receptor inhibitor
2026-05-26 — Topicort · Taro · Corticosteroid [EPC] · Formulation
2026-06-10 — Jevtana Kit · Accord Hlthcare · Microtubule Inhibitor · Compound
2026-06-16 — Arthrotec · Pfizer · diclofenac
2026-07-19 — Mitozytrex · Kyowa Kirin Co., Ltd. · Alkylating Drug [EPC] · Formulation
2026-08-14 — Cometriq · Exelixis · Kinase Inhibitor
2026-11-28 — Axumin · Blue Earth Diagnostics Ltd · Radioactive Diagnostic Agent [EPC]
2026-12-12 — Koselugo · ASTRAZENECA LP · Kinase Inhibitor [EPC]

Metabolic (13)

2026-01-20 — Ozempic · Novo Nordisk · GLP-1 Receptor Agonist [EPC]
2026-02-13 — Victoza · Novo Nordisk · GLP-1 Receptor Agonist [EPC] · Compound
2026-02-22 — Keppra · Generic (originally UCB Pharma) · Antiepileptic agent · Formulation
2026-03-13 — Tygacil · Pfizer · Tetracycline
2026-04-04 — Byetta · AstraZeneca · GLP-1 Receptor Agonist [EPC]
2026-04-09 — Amphetamine Sulfate · UCB · Central Nervous System Stimulant
2026-05-21 — Acetadote · Bristol-Myers Squibb · Antidote · Formulation
2026-05-26 — Tradjenta · Boehringer Ingelheim · Dipeptidyl Peptidase 4 Inhibitor [EPC]
2026-07-26 — Ongentys · Neurocrine Biosciences · Catechol-O-Methyltransferase Inhibitor [EPC]
2026-08-16 — Cuvposa · Shionogi · Anticholinergic
2026-08-16 — Glycopyrrolate · Yonsei University · Formulation
2026-09-15 — Differin · Galderma Labs Lp · Retinoid [EPC] · Formulation
2026-11-02 — Lyrica · Pfizer Inc. · Anticonvulsant, analgesic · Formulation

Neuroscience (7)

2026-01-26 — Bupivacaine Hydrochloride And Epinephrine · Pfizer Inc. · alpha-Adrenergic Agonist [EPC] · Formulation
2026-04-28 — Abilify · Generic (originally Otsuka/BMS) · Third-generation antipsychotic (D2 partial agonist) · Formulation
2026-05-09 — Imitrex · GSK · Serotonin-1b and Serotonin-1d Receptor Agonist · Formulation
2026-06-05 — Ritalin · Novartis · Formulation
2026-06-26 — Risperdal · Johnson & Johnson (Janssen) · Atypical Antipsychotic [EPC] · Formulation
2026-07-24 — Lignospan Forte · Fresenius Kabi · local anesthetic, amide type · Formulation
2026-07-31 — Subutex · Purdue Pharma Lp · Partial Opioid Agonist · Formulation

Immunology (7)

2026-01-27 — Sandimmune · Novartis AG (originally Sandoz) · Calcineurin inhibitor (immunosuppressant) · Formulation
2026-05-15 — Tracleer · AstraZeneca · Endothelin Receptor Antagonist · Formulation
2026-05-26 — Dovonex · Vitamin D Analog [EPC] · Formulation
2026-10-02 — SINECATECHINS · Polyphenols · Formulation
2026-11-09 — Pulmicort Respules · AstraZeneca K.K. · Corticosteroid [EPC] · Formulation
2026-11-11 — AVACINCAPTAD PEGOL SODIUM · Complement Inhibitors · Method of Use
2026-12-02 — Cleocin T · Pfizer · Lincosamide Antibacterial · Formulation

Infectious Disease (3)

2026-01-07 — Avycaz · Cerexa Inc · beta Lactamase Inhibitor [EPC]
2026-03-13 — Tygacil · Fresenius Kabi · Tetracycline-class Antibacterial [EPC]
2026-12-08 — Amoxil · Generic (originally Beecham/GSK) · Aminopenicillin (Beta-lactam antibiotic) · Compound

Cardiovascular (3)

2026-01-26 — Epipen · Pfizer Inc. · alpha-Adrenergic Agonist [EPC] · Formulation
2026-02-26 — Proventil · Merck & Co. · beta2-Adrenergic Agonist
2026-03-07 — Pradaxa · Boehringer Ingelheim · Direct thrombin inhibitor

Respiratory (3)

2026-04-05 — Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) · Thammasat University · Combination inhaler (ICS/LAMA/LABA) · Formulation
2026-07-06 — Symdeko (Copackaged) · Vertex Pharms
2026-07-06 — Trikafta (Copackaged) · Vertex Pharms Inc

Gastroenterology (2)

2026-02-27 — Xifaxan · Bausch Health · Rifamycin Antibacterial [EPC] · Method of Use
2026-06-07 — Pantoprazole Sodium · Pfizer · Proton pump inhibitor (PPI)

Pain (1)

2026-02-01 — Naloxone Hydrochloride · Pfizer Inc. · Mixed opioid agonist-antagonist with opioid antagonist · Formulation

Nephrology (1)

2026-05-12 — Xelstrym · UCB · Central Nervous System Stimulant [EPC]

Other (1)

2026-05-13 — Natazia · Mochida Pharmaceutical Co., Ltd. · Progestin

Subscribe to patent-cliff alerts

Push every new patent expiry into your RSS reader:

Biosimilar tracker — who's competing for each post-cliff originator
Patent cliff revenue calculator
2026 patent expiries dataset (CSV / JSON)